Robbins LLP Investigating Aldeyra Therapeutics for Misleading Investors

Law firm encourages shareholders who lost money to contact them about leading class action lawsuit.

Apr. 16, 2026 at 1:48am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph showing a shattered glass vial or test tube on a clean, monochromatic background, representing the unreliable clinical trial data that led to a major setback for the biotechnology company.The shattered remains of a clinical trial vial symbolize the unreliable data that led to a major setback for Aldeyra Therapeutics.San Diego Today

Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. The lawsuit alleges that Aldeyra failed to disclose inconsistent results from clinical trials of its lead drug candidate reproxalap, which the FDA later said did not demonstrate efficacy for treating dry eye disease.

Why it matters

This case highlights the importance of pharmaceutical companies fully disclosing clinical trial data and potential issues with their drug candidates, as investors rely on this information to make informed decisions. The significant stock price drop following the FDA's rejection of Aldeyra's application shows the financial impact of misleading investors.

The details

According to the complaint, Aldeyra described itself as a "biotechnology company devoted to discovering innovative therapies" but failed to disclose that the results of the reproxalap clinical trials were inconsistent and unreliable. On March 17, 2026, Aldeyra announced it had received a Complete Response Letter from the FDA stating the application lacked substantial evidence of the drug's effectiveness and that the "inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings." This news caused Aldeyra's stock price to plummet 70.7% to $1.24 per share.

  • The class period is from November 3, 2023 to March 16, 2026.
  • Aldeyra received the FDA's Complete Response Letter on March 17, 2026.
  • The deadline for shareholders to submit papers to serve as lead plaintiff is May 29, 2026.

The players

Robbins LLP

A law firm representing shareholders in a class action lawsuit against Aldeyra Therapeutics.

Aldeyra Therapeutics, Inc.

A biotechnology company that was developing a drug candidate called reproxalap to treat dry eye disease.

Got photos? Submit your photos here. ›

What they’re saying

“Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026.”

— Robbins LLP

What’s next

The lead plaintiff deadline for the class action lawsuit is May 29, 2026. Shareholders who wish to serve as lead plaintiff must submit their papers to the court by this date.

The takeaway

This case highlights the importance of pharmaceutical companies being fully transparent with investors about the results of their clinical trials, as misleading or incomplete disclosures can have significant financial consequences when regulators ultimately reject a drug application.